Welcome to our dedicated page for TIDAL TRUST III news (Ticker: DRKY), a resource for investors and traders seeking the latest updates and insights on TIDAL TRUST III stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TIDAL TRUST III's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TIDAL TRUST III's position in the market.
VistaShares (DRKY) launched the VistaShares Target 15™ DRUKMacro Distribution ETF (DRKY) on October 8, 2025.
DRKY is an actively managed ETF that generally mirrors the top publicly disclosed holdings of the Duquesne Family Office while using an options overlay that seeks 15% annual income, distributed monthly. The fund follows the same Target 15™ design used by VistaShares’ OMAH and ACKY ETFs; OMAH has gathered nearly $600 million since March 5, 2025, and ACKY exceeded $30 million in assets in three weeks. DRKY is not affiliated with Duquesne or Stanley Druckenmiller.
FAQ
What is the current stock price of TIDAL TRUST III (DRKY)?
